follicular lymphoma epidemiology forecast insight

DelveInsight’s ‘Follicular Lymphoma – Epidemiology Forecast – 2034’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Follicular Lymphoma in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Follicular Lymphoma: Disease Understanding

Follicular Lymphoma Overview

Follicular lymphoma (FL) is generally an indolent B cell lymphoproliferative disorder of transformed follicular center B cells. It is characterized by diffuse lymphadenopathy, bone marrow involvement, and splenomegaly. Extranodal involvement is less common. Cytopenias are relatively common, but constitutional symptoms of fever, night sweats, and weight loss are uncommon in the absence of transformation to diffuse large B cell lymphoma.

Common symptoms of FL include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. Often, patients with FL have no apparent symptoms of the disease at diagnosis. Follicular lymphoma is usually not considered to be curable but more of a chronic disease. Besides, patients can live for many years with this form of lymphoma.

The World Health Organization (WHO) (2017) has a grading system (Grade 1, 2, or 3) for FL that depends on the percentage of centroblasts, and is as follows: grade 1 (follicular small cleaved): 0 – 5 centroblasts/HPF, grade 2 (follicular mixed): 6–15 centroblasts/HPF, grade 3 (follicular large cell): > 15 centroblasts/HPF (grade 3A - centrocytes present, grade 3B - solid sheets of centroblasts). It is clinically important to differentiate grades 1/2 vs. grade 3.

The diagnosis is based on histology from a biopsy of a lymph node or other affected tissue. Incisional biopsy is preferred over needle biopsies to give adequate tissue to assign grades and assess for transformation. Immunohistochemical staining is positive in virtually all cases for cell surface CD19, CD20, CD10, and monoclonal immunoglobulin, as well as cytoplasmic expression of bcl-2 protein. The overwhelming majority of cases have the characteristic t(14;18) translocation involving the IgH/bcl-2 genes.

The management of FL depends on the disease stage. Options available for the treatment of follicular lymphoma include radiation (RT), immunochemotherapy (Rituximab plus chemotherapy), Bundamustine with immunotherapy, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) plus obinutuzumabe or rituximab, CVP (cyclophosphamide, vincristine, prednisone) plus obinutuzumabe or rituximab, immunochemotherapy plus radiation therapy, single-agent rituximab, and observation until progression. The choice of regimen depends on the stage of the disease, physician preference, and patient preference.

With the recent approval of Yescarta for indolent follicular lymphoma, CAR T cells appear promising for follicular lymphoma. Kymirah (Novartis) and Breyanzi (BMS) are the key CART therapy currently in the pipeline for treating patients with relapsed/refractory FL. There may be a specific group of follicular patients that may benefit most from this therapy.

The newer bispecific antibodies (Mosunetuzumab and Ordonextamab) appear to be a promising asset, with less toxicity and just easier administration access for patients.

Follicular Lymphoma: Epidemiology

The Follicular Lymphoma epidemiology division provides insights into the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Follicular Lymphoma epidemiology segmented as the Incident cases of Follicular Lymphoma, Grade-specific cases of Follicular Lymphoma, Age-specific cases of Follicular Lymphoma, and Stage-specific cases of Follicular Lymphoma. The report includes the incident scenario of Follicular Lymphoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country-wise Follicular Lymphoma Epidemiology

The epidemiology segment also provides the Follicular Lymphoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• The total incident population of Follicular Lymphoma in the 7MM countries was estimated to be 35,737 cases in 2020.
• As per the estimates, the United States had the largest incidence of Follicular Lymphoma in 2020. Among the EU5 countries, Germany had the largest incident population of Follicular Lymphoma with 3,710 cases, followed by the United Kingdom in 2020. On the other hand, Spain had the lowest incident population of 1,640 cases in 2020.

Scope of the Report

• Follicular Lymphoma report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Follicular Lymphoma Epidemiology Report and Model provide an overview of the risk factors and global Follicular Lymphoma trends in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Follicular Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Follicular Lymphoma.
• The report provides the segmentation of the Follicular Lymphoma epidemiology by Incident cases of Follicular Lymphoma in the 7MM.
• The report provides the segmentation of the Follicular Lymphoma epidemiology by Grade-specific cases of Follicular Lymphoma in the 7MM.
• The report provides the segmentation of the Follicular Lymphoma epidemiology by the Age-specific cases of Follicular Lymphoma in the 7MM
• The report provides the segmentation of the Follicular Lymphoma epidemiology by the Stage-specific cases of Follicular Lymphoma in the 7MM.

Report Highlights

• 10-year Forecast of Follicular Lymphoma epidemiology
• 7MM Coverage
• Incident cases of Follicular Lymphoma
• Grade-specific cases of Follicular Lymphoma
• Age-specific cases of Follicular Lymphoma
• Stage-specific cases of Follicular Lymphoma

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM for the patient population pertaining to Follicular Lymphoma?
• What are the key findings pertaining to the Follicular Lymphoma epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2034)?
• What would be the total number of patients with Follicular Lymphoma across the 7MM during the forecast period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021-2034)?
• What are the disease risk, burdens, and unmet needs of Follicular Lymphoma?
• What are the currently available treatments for Follicular Lymphoma?

Reasons to buy

Follicular Lymphoma Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Follicular Lymphoma market
• Quantify patient populations in the global Follicular Lymphoma market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Follicular Lymphoma therapeutics in each of the markets covered
• Understand the magnitude of the Follicular Lymphoma population by its Incident cases of Follicular Lymphoma
• Understand the magnitude of the Follicular Lymphoma population by its Grade-specific cases of Follicular Lymphoma.
• Understand the magnitude of the Follicular Lymphoma population by its Age-specific cases of Follicular Lymphoma.
• Understand the magnitude of the Follicular Lymphoma population by its Stage-specific cases of Follicular Lymphoma.
• The Follicular Lymphoma epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Follicular Lymphoma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population